Belite Bio (BLTE) Return on Invested Capital (2023 - 2024)
Belite Bio (BLTE) recorded quarterly Return on Invested Capital of 2.21% in Q4 2024, up 12.12% quarter-over-quarter from 2.52% in Q3 2024, and down 125.0% on a YoY basis from 8.85% in Q1 2024.
Belite Bio (BLTE) Return on Invested Capital (2023 - 2024) Analysis & Trends
Belite Bio's Return on Invested Capital history runs 2 years deep, the most recent figure standing at 2.21% for Q4 2024.
- In Q4 2024, Return on Invested Capital fell 125.0% year-over-year to 2.21%; the TTM figure through Dec 2024 stood at 2.21% (down 125.0% YoY), while the FY2024 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital was 2.21% for Q4 2024 at Belite Bio, up from 2.52% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.96% in Q4 2023 to a low of 2.52% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.01% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -0.01% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -0.01% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.21% |
| Sep 30, 2024 | -2.52% |
| Jun 30, 2024 | -1.78% |
| Mar 31, 2024 | -1.63% |
| Dec 31, 2023 | -0.96% |